New York, New York 10029

  • Chalazion

Purpose:

The purpose of this study is to evaluate the efficacy and safety of SUN-131 1.5% TDS as compared with placebo TDS in the treatment of chalazion based on the proportion of subjects that have complete response. Complete response is defined as the absence of any significant clinical signs of a chalazion with possible scaring or skin defects resulting from healing of the chalazion allowed.


Study summary:

Subjects will be randomly assigned to receive one of the following treatments in the affected eyelid: - SUN-131 1.5% TDS (n=30) - Placebo TDS (n=30) At baseline prior to application of the TDS an assessment will be performed on both the subject's eyes including the chalazion site itself. All subjects will return to the site on Days 8±1, 15±2 and 23±2 for evaluations. During the the 23±2 visit, a clinical evaluation will be performed to determine if the chalazion is still present. There will also be follow up on Day 29±3, and on Day 50 visit (study days 47 to 60) to evaluate the safety and durability of the effect of the SUN-131 1.5% TDS. Data review and safety assessments will be conducted by the medical monitor periodically throughout the trial and at the conclusion of the study.


Criteria:

Inclusion Criteria: - 18 years of age or older of either sex and any race - Chalazion with visible single granuloma in an upper or lower eyelid. If more than one eyelid is diagnosed with a chalazion, the most inflammatory chalazion shall be selected as the study eyelid. Other eyelids containing a chalazion will not be treated with investigational product in this trial. - Chalazion intended for study treatment presents no more than 3 weeks based on subject history. - Normal lid function - Must be willing and able to correctly apply and wear a transdermal patch to the eyelid for 16±4 hours each day for repeated application - Female subjects of childbearing potential must have a negative urine pregnancy test on Day 1, and must agree to use method of contraception from the start of study drug use and for 30 days after discontinuation of study drug. Approved methods of contraception include, an IUD with spermicide, a female condom with spermicide, a diaphragm with spermicide, a cervical cap with spermicide, use of a condom with spermicide by sexual partner or a sterile sexual partner or oral contraceptives. - If male, subjects must be sterile or willing to use an approved method of contraception from the time of study drug administration to 30 days after discontinuation of study drug. Males must be willing to refrain from sperm donation within 30 days after study drug treatment. - Are able and willing to attend all study visits and follow all study instructions. - Have signed written informed consent before undergoing any study related procedures and is willing to comply with all study procedures. - Avoid wearing contact lenses or any new facial cosmetic products during the study trial period. Exclusion Criteria: - Chalazion which have atypical features (a recurring chalazion at the same spot, abnormal surrounding lid tissue, associated loss of tissues). - Chalazion at the lid margin. - Active ocular or eyelid infection (bacterial, viral, or fungal), any ocular or eyelid condition that in the investigator's opinion could affect the subject's health or the study parameters. - An abnormal skin condition on the upper and lower eyelid region of the eyelid (e.g. eczema, psoriasis, etc.) where the patches will be applied. - Intraocular pressure greater than 22 mmHg. - Diagnosed with glaucoma. - Use of oral and ocular therapy with a steroid within 7 days prior to administration of the study medication and during the study. - Female subjects who are pregnant or lactating. - Known allergy or sensitization to the test article or any formulation components. - Major non-ocular surgery within 30 days prior to Day 1. - History or evidence of ocular surgery within the past 3 months and/or a history of refractive surgery within the past 6 months. - Planned surgery (ocular or systemic) during the trial period or within 30 days of removal of the transdermal patch. - Participation in an investigational study within 30 days prior to Day 1. - Have any ocular condition that requires chronic use of topical ophthalmic medication (e.g., glaucoma, dry eye, allergic conjunctivitis) with exception of artificial tear drops or lubricant eye drops or that, in the investigator's opinion, prevents the safe use of the patch. - History of any previous functional or cosmetic eyelid surgery (including blepharopigmentation). - Any other condition that, in the opinion of the investigator, renders the subject unsuitable for study participation.


Study is Available At:


Original ID:

SUN-131-02


NCT ID:

NCT02338648


Secondary ID:


Study Acronym:


Brief Title:

Safety and Efficacy Study of SUN 131 TDS as Compared to Placebo TDS in Adult Patients With a Chalazion


Official Title:

A Multi-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of SUN 131 Transdermal System (TDS) as Compared to Placebo TDS in Adult Patients With a Chalazion


Overall Status:

Completed


Study Phase:

Phase 2


Genders:

N/A


Minimum Age:

18 Years


Maximum Age:

N/A


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Senju USA, Inc.


Oversight Authority:

United States: Food and Drug Administration


Reasons Why Stopped:


Study Type:

Interventional


Study Design:


Number of Arms:

2


Number of Groups:

0


Total Enrollment:

60


Enrollment Type:

Actual


Study Dates

Start Date:October 2014
Completion Date:January 2016
Completion Type:Actual
Primary Completion Date:January 2016
Primary Completion Type:Actual
Verification Date:June 2017
Last Changed Date:August 9, 2017
First Received Date:October 31, 2014

Study Outcomes

Outcome Type:Secondary Outcome
Measure:Comparison of Adverse Event Rates and Skin Irritation between Treatment Arms
Time Frame:Day 23±2
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Durability of Response
Time Frame:Study days 47 to 60
Safety Issues:False
Description:Clinical assessment of the presence of a chalazion if there was a complete response by Day 23±2.
Outcome Type:Secondary Outcome
Measure:Time to Complete Response of the Target Chalazion
Time Frame:Study days 47 to 60
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Pain Associated with the Chalazion
Time Frame:Study days 47 to 60
Safety Issues:False
Description:Pain assessments will be done at the clinical site using a 100 mm visual analog scale.
Outcome Type:Secondary Outcome
Measure:Change in Chalazion Erythema
Time Frame:Study days 47 to 60
Safety Issues:False
Description:Erythema of the chalazion site itself will be assessed using a 5-point scale (i.e. 0 = no signs of erythema; to 4 = severe erythema)
Outcome Type:Secondary Outcome
Measure:Change in Chalazion Size
Time Frame:Study days 47 to 60
Safety Issues:False
Description:Size of the chalazion will be assessed using a caliper and measured as height and width in mm.
Outcome Type:Primary Outcome
Measure:Complete Response
Time Frame:Day 23±2
Safety Issues:False
Description:Complete response is defined as the absence of any significant clinical signs of a chalazion with possible scaring or skin defects resulting from healing of the chalazion allowed.

Study Interventions

Intervention Type:Drug
Name:SUN-131 1.5% TDS
Description:Active transdermal patch
Arm Name:SUN-131 1.5% TDS
Intervention Type:Drug
Name:Placebo TDS
Description:Placebo transdermal patch for blinding
Arm Name:Placebo TDS

Study Arms

Study Arm Type:Experimental
Arm Name:SUN-131 1.5% TDS
Description:Subjects will be randomly assigned to receive SUN-131 1.5% TDS for the affected eye. All patches will be worn for 16±4 hours each day for 21 days.
Study Arm Type:Placebo Comparator
Arm Name:Placebo TDS
Description:Placebo Patch for Blinding Purposes

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Senju USA, Inc.

Sample and Retention Information

There are no available Sample and Retention Information

Study References

Reference Type:Results Reference
Citation:Elsevier BH. Clinical Ocular Pharmacology. 5th Edition ed2008.
Reference Type:Results Reference
Citation:Ben Simon GJ, Rosen N, Rosner M, Spierer A. Intralesional triamcinolone acetonide injection versus incision and curettage for primary chalazia: a prospective, randomized study. Am J Ophthalmol. 2011 Apr;151(4):714-718.e1. doi: 10.1016/j.ajo.2010.10.026. Epub 2011 Jan 22.
PMID:21257145
Reference Type:Results Reference
Citation:Ben Simon GJ, Huang L, Nakra T, Schwarcz RM, McCann JD, Goldberg RA. Intralesional triamcinolone acetonide injection for primary and recurrent chalazia: is it really effective? Ophthalmology. 2005 May;112(5):913-7.
PMID:15878075
Reference Type:Results Reference
Citation:Kaimbo Wa Kaimbo D, Nkidiaka MC. [Intralesional corticosteroid injection in the treatment of chalazion]. J Fr Ophtalmol. 2004 Feb;27(2):149-53. French.
PMID:15029042
Reference Type:Results Reference
Citation:Ho SY, Lai JS. Subcutaneous steroid injection as treatment for chalazion: prospective case series. Hong Kong Med J. 2002 Feb;8(1):18-20.
PMID:11861988
Reference Type:Reference
Citation:Draize JH. Dermal toxicity. Appraisal of Chemicals in Food, Drugs and Cosmetics: The Association of Food and Drug Officials of the United States (3rd printing 1975); 1959. p. 46-59
Reference Type:Reference
Citation:Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med. 2005 Oct 20;353(16):1711-23. Review.
PMID:16236742

Data Source: ClinicalTrials.gov

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


This study is not currently recruiting Study Participants. The form below is not enabled.